These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34488370)

  • 1. Mutational characteristics of bone metastasis of lung cancer.
    Huang X; Shi X; Huang D; Li B; Lin N; Pan W; Yan X; Li H; Hao Q; Ye Z
    Ann Palliat Med; 2021 Aug; 10(8):8818-8826. PubMed ID: 34488370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases.
    Stein MK; Pandey M; Xiu J; Tae H; Swensen J; Mittal S; Brenner AJ; Korn WM; Heimberger AB; Martin MG
    JCO Precis Oncol; 2019 Dec; 3():1-13. PubMed ID: 35100709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Landscape of Metastatic Lymph Nodes and Primary Tumors in Non-Small-Cell Lung Cancer.
    Chen B; Li R; Zhang J; Xu L; Jiang F
    Pathol Oncol Res; 2022; 28():1610020. PubMed ID: 35783357
    [No Abstract]   [Full Text] [Related]  

  • 5. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal Growth Factor Receptor Gene Mutation Status in Primary Lung Adenocarcinoma and Corresponding Bone Metastases.
    Shi PX; Li YT; Wang SY; Sun RZ; Xu HT; Dong QZ; Zhao Y; Wang EH; Liu Y
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):49-56. PubMed ID: 30601156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer.
    Wang S; Wang Z
    Clin Oncol (R Coll Radiol); 2015 Jan; 27(1):30-9. PubMed ID: 25445553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.
    Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K
    Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The co-mutation of
    Zhang Y; Li S; Lyu Z; Cai J; Zheng N; Li Y; Xu T; Zeng H
    J Thorac Dis; 2022 Jan; 14(1):185-193. PubMed ID: 35242380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
    Wang H; Ou Q; Li D; Qin T; Bao H; Hou X; Wang K; Wang F; Deng Q; Liang J; Zheng W; Wu X; Wang X; Shao YW; Mou Y; Chen L
    Cancer; 2019 Oct; 125(20):3535-3544. PubMed ID: 31287555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
    Becerra MF; Reznik E; Redzematovic A; Tennenbaum DM; Kashan M; Ghanaat M; Casuscelli J; Manley B; Jonsson P; DiNatale RG; Blum KA; Durack JC; Solomon SB; Arcila ME; Bourque C; Socci N; Carlo MI; Lee CH; Voss MH; Feldman DR; Motzer RJ; Coleman JA; Russo P; Cheng EH; Hakimi AA; Hsieh JJ
    Eur Urol Focus; 2018 Dec; 4(6):986-994. PubMed ID: 29066084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
    Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
    Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.
    Daniele L; Cassoni P; Bacillo E; Cappia S; Righi L; Volante M; Tondat F; Inghirami G; Sapino A; Scagliotti GV; Papotti M; Novello S
    J Thorac Oncol; 2009 Jun; 4(6):684-8. PubMed ID: 19404216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis.
    Fujimoto D; Ueda H; Shimizu R; Kato R; Otoshi T; Kawamura T; Tamai K; Shibata Y; Matsumoto T; Nagata K; Otsuka K; Nakagawa A; Otsuka K; Katakami N; Tomii K
    Clin Exp Metastasis; 2014 Jun; 31(5):543-51. PubMed ID: 24682604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
    Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma.
    Dormieux A; Mezquita L; Cournede PH; Remon J; Tazdait M; Lacroix L; Rouleau E; Adam J; Bluthgen MV; Facchinetti F; Tselikas L; Aboubakar F; Naltet C; Lavaud P; Gazzah A; Le Pechoux C; Lassau N; Balleyguier C; Planchard D; Besse B; Caramella C
    Eur Radiol; 2020 Sep; 30(9):5021-5028. PubMed ID: 32323012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
    J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic landscape of metastatic lung adenocarcinomas from large-scale clinical sequencing.
    Li D; Huang Y; Cai L; Wu M; Bao H; Xu Y; Wei Y; Wu S; Wu X; Shao Y; Zhao W; Lv G; Huang S; Zhang T; Shi Y
    Neoplasia; 2021 Dec; 23(12):1204-1212. PubMed ID: 34735995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.